Ikarian Capital’s Praxis Precision Medicines PRAX Stock Holding History

Ikarian Capital’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.4M	Buy	72,842 +1,261	+2%	+$399K	2.63%	9
2026 Q1	$23.1M	Sell	71,581 -15,000	-17%	-$4.64M	1.87%	13
2025 Q4	$25.5M	Buy	86,581 +58,010	+203%	+$10.8M	1.99%	10
2025 Q3	$1.51M	Sell	28,571 -248,379	-90%	-$12M	0.15%	107
2025 Q2	$11.6M	Buy	276,950 +131,448	+90%	+$5.01M	2.24%	13
2025 Q1	$5.51M	Buy	+145,502	New	+$9.09M	0.68%	32
2024 Q2	–	Sell	-168,388	Closed	-$7.96M	–	147
2024 Q1	$10.3M	Sell	168,388 -31,612	-16%	-$1.42M	1.13%	27
2023 Q4	$4.46M	Buy	200,000 +50,000	+33%	+$901K	0.42%	63
2023 Q3	$3.85M	Buy	+150,000	New	+$2.84M	0.46%	57
2023 Q1	–	Sell	-10,000	Closed	-$357K	–	130
2022 Q4	$357K	Buy	+10,000	New	+$312K	0.09%	65
2021 Q1	–	Sell	-333	Closed	-$275K	–	324
2020 Q4	$275K	Buy	+333	New	+$194K	0.01%	208

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Ikarian Capital's PRAX Position: Q2 2026 in Review

Ikarian Capital increased its Praxis Precision Medicines (PRAX) stake by 1.8% in Q2 2026, buying an estimated $399K and bringing the position to 72,842 shares worth $24.4M. The position accounts for 2.63% of the portfolio, ranked #9.

Ikarian Capital first reported a position in PRAX in Q4 2020 and has held it in 11 quarters since. The position peaked at $25.5M in Q4 2025. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Ikarian Capital held 72,842 shares of Praxis Precision Medicines worth $24.4M as of Q2 2026.
Ikarian Capital bought 1,261 Praxis Precision Medicines shares in Q2 2026, an estimated $399K.
Praxis Precision Medicines made up 2.63% of Ikarian Capital's portfolio in Q2 2026, its #9 holding.
Ikarian Capital first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 11 quarters since.
Ikarian Capital's Praxis Precision Medicines position peaked at $25.5M in Q4 2025.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.